Literature DB >> 31464238

Calcification of abdominal aorta in patients recently starting hemodialysis: A single-center experience from Egypt.

Ahmed Fayed1, Mahmoud M Elnokeety1, Khaled Attia1, Usama A Sharaf El Din1.   

Abstract

Vascular calcification (VC) is a well-known complication in patients with chronic kidney disease (CKD). Keeping in mind, the end goal to assess the genuine effect of mineral bone disease in the pathogenesis of blood vessel calcification during the pre-dialysis course of CKD, we assessed the prevalence and extent of abdominal aortic calcification (AAC) in nondiabetic CKD patients recently starting hemodialysis (HD). Eighty-one patients with end-stage renal disease beginning HD over a one-month period were selected. They underwent a detailed clinical examination and laboratory evaluation, including serum calcium, phosphorus, parathyroid hormone, fibroblast growth factor (FGF-23), and alkaline phosphatase were measured, and spiral computed tomography was performed to evaluate AAC score. AAC was present in 64 patients (79%). There was a significant correlation between the AAC score and age (r = 0.609, P <0.001) and FGF-23 (r = 0.800, P <0.001). This study suggests that the prevalence and extent of AAC are critical in incident HD patients. Serum FGF-23 level is the sole statistically significant correlate of AAC in these patients.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31464238     DOI: 10.4103/1319-2442.265457

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  2 in total

1.  Vascular Calcification in Chronic Kidney Disease: An Update and Perspective.

Authors:  Si-Chong Ren; Nan Mao; Si Yi; Xin Ma; Jia-Qiong Zou; Xiaoqiang Tang; Jun-Ming Fan
Journal:  Aging Dis       Date:  2022-06-01       Impact factor: 9.968

2.  Relationship between serum parathyroid hormone levels and abdominal aortic calcification in patients starting hemodialysis who have never taken calcium tablets, calcitriol, or vitamin D analogs.

Authors:  Jin He; Xiaoyan Sun; Rongjian Nie; Lin Zhao
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.